All cards
BONES, JOINTS & MUSCLESGlucosamine: what the bigtrials found1GAIT (NEJM 2006): pain response placebo 60%,glucosamine 64%, chondroitin 65%, both 67% — nonesignificant2BMJ 2010 (3,803 people): pain improved 0.3–0.5 cm ona 10-cm scale, below the 0.9 cm that mattersclinically3Joint-space change on X-ray same as placebo — no“cartilage repair”4Industry-funded trials showed 0.5 cm more effect thanindependent ones5ACR 2019, OARSI 2019 and NICE 2022 all recommendagainst6What works: exercise therapy and weight loss (each kglost cuts knee load by about 4 kg)Kidney patients: some products carry potassium or sodium; possibleinteraction with warfarin. Fairly safe — just don’t skip theexercise.BBeyond CKDbeyondckd.com/en/cards/glucosamine-what-trials-foundSources: Clegg DO et al. GAIT · Wandel S et al. Glucosamine/chondroitin network…Compiled from public clinical guidelines · General education, not individual medical advice
LINE Facebook

Bones, joints & muscles

Glucosamine: what the big trials found

Ten years on glucosamine? Here’s the NIH 1,583-person trial and the BMJ meta-analysis.

  1. 1GAIT (NEJM 2006): pain response placebo 60%, glucosamine 64%, chondroitin 65%, both 67% — none significant
  2. 2BMJ 2010 (3,803 people): pain improved 0.3–0.5 cm on a 10-cm scale, below the 0.9 cm that matters clinically
  3. 3Joint-space change on X-ray same as placebo — no “cartilage repair”
  4. 4Industry-funded trials showed 0.5 cm more effect than independent ones
  5. 5ACR 2019, OARSI 2019 and NICE 2022 all recommend against
  6. 6What works: exercise therapy and weight loss (each kg lost cuts knee load by about 4 kg)

Kidney patients: some products carry potassium or sodium; possible interaction with warfarin. Fairly safe — just don’t skip the exercise.

Caption (ready to paste)

Ten years on glucosamine? Here’s the NIH 1,583-person trial and the BMJ meta-analysis.

1. GAIT (NEJM 2006): pain response placebo 60%, glucosamine 64%, chondroitin 65%, both 67% — none significant
2. BMJ 2010 (3,803 people): pain improved 0.3–0.5 cm on a 10-cm scale, below the 0.9 cm that matters clinically
3. Joint-space change on X-ray same as placebo — no “cartilage repair”
4. Industry-funded trials showed 0.5 cm more effect than independent ones
5. ACR 2019, OARSI 2019 and NICE 2022 all recommend against
6. What works: exercise therapy and weight loss (each kg lost cuts knee load by about 4 kg)

Kidney patients: some products carry potassium or sodium; possible interaction with warfarin. Fairly safe — just don’t skip the exercise.

Sources: Clegg DO et al. GAIT — N Engl J Med 2006; Wandel S et al. Glucosamine/chondroitin network meta-analysis — BMJ 2010
Verified: 2026-10-17

Cards and scripts are general health education compiled from public clinical guidelines. They are not individual medical advice and do not replace assessment by your doctor, pharmacist or dietitian. Please keep the sources and this notice when sharing; this page holds the latest version.
https://beyondckd.com/en/cards/glucosamine-what-trials-found
60-second short-video script

Shot list and voice-over. Vertical 9:16; put captions in the lower third. Every line maps to the sources on the left.

secScreenVoice-over
0–5Glucosamine jarAll these years — did it work?
5–25GAIT five barsThe NIH-funded GAIT trial: placebo 60%, glucosamine 64%, chondroitin 65%, both 67% — none significant.
25–45BMJ 0.9 cm thresholdBMJ pooled ten large trials: pain improved only 0.3 to 0.5 cm; joint space changed the same as placebo.
45–60Exercise + scaleGuidelines recommend against it. What works is exercise and weight loss — every kilo lost takes four off your knees.

Sources (every point on the card maps to one)

Verified: 2026-10-17